AusDiagnostics TODAY

AusDiagnostics



Puryx[®] Access & MT-Prep[™] Access

Convenient, high-throughput nucleic acid extraction for up to 96 samples in 30 minutes.

Features and benefits

- Simple Peel, Load, Go workflow
- Pre-loaded reagent plates are ready to use with no reconstitution, buffers, or alcohols required
- Attain DNA or RNA from up to 1,440 primary samples in an 8 hour period
- Intuitive reagent plate loading in less than 2 minutes
- Easy-to-use in-built touchscreen to save space





PEEL

Peel foil off the pre-loaded reagent plates.



LOAD

Load reagent plates in clearly labelled slots on the MT-Prep™ Access.



GO

Initialise and walk away for optimal convenience.

Learn more at <u>ausdiagnostics.com/mt-prep-access</u>

NEW products coming in 2022

High-throughput solution for targeted testing

Point-of-care SARS-CoV-2 diagnostics

Upcoming events

MedLab 2022

Connect with our team to discuss diagnostics technology at the conference in Dubai.

24 – 27 January 2022 Dubai World Trade Centre, UAE

ECCMID 2022

Join us at the 32nd European Congress of Clinical Microbiology & Infectious Diseases.

23 – 26 April 2022 Lisbon, Portugal, & Online At AusDiagnostics, 2021 was the year of collaboration with new staff, partnerships, and markets.

New Head of Quality, EMEA

Jon Keating joined AusDiagnostics in October as our new Head of Quality for Europe, Middle East, and Africa.



Jon Keating Head of Quality, EMEA

Jon brings aboard over 20 years of expertise in *in vitro* medical devices.

One of Jon's key objectives is to improve our Quality Management systems in the United Kingdom to ensure our ongoing compliance with ISO 13485 and IVDR.

We are delighted to welcome Jon to AusDiagnostics.

Forging New Partnerships in EMEA

For the first time in two years, sales staff from AusDiagnostics UK were able to visit Medica-Dusseldorf and ARABLAB-Dubai.

The meeting allowed us to continue conversations to add to our network of distributors and partner organisations.



We greatly value the connections we have with our partners, without whom we would be unable to improve the standard of healthcare globally, including our expanded capabilities to provide solutions to new EMEA markets.

Message from the CEO

This year we have developed faster and more reliable methods of detecting SARS-CoV-2 than ever before.

These achievements are a testament to the dedication and talents of the AusDiagnostics community.

I am continually amazed by the capabilities of our employees, partners, and customers, and I am grateful to work with alongside them.



Scott Gilroy Chief Executive Officer

© 2021 AusDiagnostics Pty Ltd. All rights reserved. AusDiagnostics, Puryx, and MT–Prep are trademarks of AusDiagnostics Pty Ltd. E&OE. NL21Q4003 16 Dec 2021.

Our Newsletters are changing.

From 2022, we're changing the way we share company news and updates.

You will be able to view all of the information directly within the email, rather than a PDF document.

Are you subscribed?

Sign up to receive future newsletters at ausdiagnostics.com/support

